{"brief_title": "Depression in Alzheimer's Disease-2", "brief_summary": "The purpose of this study is to learn whether treating individuals with Alzheimer's disease and depression with the anti-depressant medication sertraline (Zoloft) is helpful to people with Alzheimer's disease and to their families and caregivers.", "detailed_description": "Participants are randomly assigned to treatment with sertraline (range 25-125 mg per day) or identical placebo for 24 weeks. There are 8 scheduled in-person visits in the 24 weeks. Visits include neuropsychological testing. Caregivers are asked to are the patient on a Daily Affect Diary for 6 weeks during the study period. Telephone followup is done at weeks 36 and 48. Both groups receive caregiver support/education.", "condition": "Depression", "intervention_type": "Drug", "intervention_name": "Placebo", "description": "Placebo designed to mimic sertraline taken daily for 24 weeks", "arm_group_label": "2", "criteria": "Inclusion: - Ability of the participant, caregiver or surrogate to provide written informed consent. - Dementia due to Alzheimer's disease - Stable treatment for Alzheimer's disease - Ability for the participant's caregiver to accompany the participant to study visits and participate in the study. Exclusion - Presence of a brain disease that might otherwise explain the presence of dementia - Clinically significant hallucinations or delusions - Current treatment of antipsychotics, anticonvulsants, and other antidepressants, benzodiazepines, or other psychotropic medications - Need for hospitalization or residence in a nursing facility", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00086138.xml"}